Lionel Ades, MD, PhD, Avicenne Hospital, Bobigny, France, outlines the current challenges facing high-risk myelodysplastic syndromes (MDS) treatment. Specifically discussed is improving the results of hypomethylating agents such as azacitidine with other agents and the subsequent issue of side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).